134 related articles for article (PubMed ID: 17468345)
1. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
Mari A; Degn K; Brock B; Rungby J; Ferrannini E; Schmitz O
Diabetes Care; 2007 Aug; 30(8):2032-3. PubMed ID: 17468345
[No Abstract] [Full Text] [Related]
2. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
[TBL] [Abstract][Full Text] [Related]
3. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide in the management of type 2 diabetes.
Wajcberg E; Amarah A
Drug Des Devel Ther; 2010 Oct; 4():279-90. PubMed ID: 21116334
[TBL] [Abstract][Full Text] [Related]
6. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
7. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
[No Abstract] [Full Text] [Related]
9. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Vilsbøll T; Zdravkovic M; Le-Thi T; Krarup T; Schmitz O; Courrèges JP; Verhoeven R; Bugánová I; Madsbad S
Diabetes Care; 2007 Jun; 30(6):1608-10. PubMed ID: 17372153
[No Abstract] [Full Text] [Related]
10. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
[TBL] [Abstract][Full Text] [Related]
12. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
Consoli A; Di Biagio R
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide: a once-daily human glucagon-like peptide-1 analogue.
Aimaretti G
J Endocrinol Invest; 2009 Sep; 32(8):701-3. PubMed ID: 19942822
[No Abstract] [Full Text] [Related]
14. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
15. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
Kielgast U; Krarup T; Holst JJ; Madsbad S
Diabetes Care; 2011 Jul; 34(7):1463-8. PubMed ID: 21593296
[TBL] [Abstract][Full Text] [Related]
16. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells.
Ma X; Guan Y; Hua X
J Diabetes; 2014 Sep; 6(5):394-402. PubMed ID: 24725840
[TBL] [Abstract][Full Text] [Related]
18. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
[TBL] [Abstract][Full Text] [Related]
19. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
Zheng J; Chen T; Zhu Y; Li HQ; Deng XL; Wang QH; Zhang JY; Chen LL
Exp Biol Med (Maywood); 2015 Sep; 240(9):1165-76. PubMed ID: 25710926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
